Introduction {#section5-1758835918793849}
============

The lifetime incidence rate of female invasive breast cancer in the United States (US) is approximately 12% (one in eight women), and it is estimated that over 266,120 new cases of locally advanced or metastatic breast cancer, collectively referred to from hereon as advanced breast cancer (ABC), will be diagnosed in 2018.^[@bibr1-1758835918793849]^ Approximately 70% of breast cancer cases are of the luminal subtype or estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2--)^[@bibr2-1758835918793849]^ and, for some time at least, are typically responsive to endocrine therapy. Sequential endocrine therapy, or endocrine-based therapy \[e.g. palbociclib plus letrozole is now a National Comprehensive Cancer Network (NCCN) category 1 option for postmenopausal patients with advanced disease and no prior endocrine therapy within 1 year\], is therefore considered the mainstay treatment for premenopausal and postmenopausal patients with *de novo* or recurrent hormone receptor positive (HR+)/HER2-- ABC.^[@bibr3-1758835918793849]^ Current NCCN guidelines recommend sequential endocrine therapy until three successive endocrine therapy regimens offer no clinical benefit or until symptomatic visceral disease develops.^[@bibr3-1758835918793849]^ Similarly, the American Society of Clinical Oncology guidelines recommend sequential endocrine treatment, except in the event of immediately life-threatening HR+ ABC.^[@bibr4-1758835918793849]^ After first-line treatment, preferably with aromatase inhibitors (AIs) in postmenopausal women and tamoxifen or an AI in conjunction with ovarian suppression for premenopausal women without prior exposure to hormone therapy, endocrine agents can be given in any particular order for endocrine-responsive disease.^[@bibr4-1758835918793849]^

Despite major advances in our understanding of the heterogeneity, biology, and genomics of ABC over the past 2 decades,^[@bibr2-1758835918793849]^ the median survival rate after diagnosis of HR+ ABC has not exceeded 2--3 years and reflects the correspondingly modest improvement in disease management over the same period.^[@bibr5-1758835918793849]^ Although endocrine agents are generally well tolerated, resistance to endocrine therapy *via* various mechanisms is likely to occur over time in cases of ABC.^[@bibr2-1758835918793849],[@bibr6-1758835918793849],[@bibr7-1758835918793849]^ Hence, the addition of a targeted biological therapy to delay the onset of endocrine resistance and disease progression has emerged as an innovative and promising treatment option.^[@bibr7-1758835918793849]^ This article provides a comprehensive review of the pharmacology, efficacy, and safety of palbociclib, a first-in-class inhibitor of cyclin-dependent kinases (CDK) 4 and 6 indicated for use in combination with endocrine therapy in first-line treatment and as therapy after disease progression on prior endocrine therapy for advanced cancer (an AI and fulvestrant, respectively) in patients with HR+ metastatic breast cancer or ABC.^[@bibr8-1758835918793849],[@bibr9-1758835918793849]^ As of 12 February 2018, palbociclib in combination with endocrine therapy is an approved treatment for ABC in 82 countries; 79 of these countries are approved for the dual indication, including 48 for palbociclib plus AIs and 31 specifically for palbociclib plus letrozole.

Pharmacology {#section6-1758835918793849}
============

Mechanism of action {#section7-1758835918793849}
-------------------

Palbociclib is a highly selective inhibitor of CDK 4 and CDK 6 that has been approved by the US Food and Drug Administration (FDA) to treat HR+/HER2− ABC in combination with endocrine therapy.^[@bibr8-1758835918793849]^ These two serine/threonine family kinases are part of the cyclin D--CDK 4/6--INK4--retinoblastoma protein (pRb) signaling pathway downstream of numerous mitogenic cascades.^[@bibr10-1758835918793849][@bibr11-1758835918793849]--[@bibr12-1758835918793849]^ When this signaling pathway is affected by various genetic or molecular perturbations, including but not limited to cyclin D overexpression, *CCND1* amplification, the loss of function of pRb, or the tumor suppressor p16 (*CDKN2A* loss),^[@bibr13-1758835918793849],[@bibr14-1758835918793849]^ CDK 4/6 activation is implicated in the cellular dysregulation that is characteristic of malignant breast cancer cells. The CDK 4/6 inhibitory activity of palbociclib leads to reduced pRb phosphorylation at serine residues 780 and 795 in Rb+ cells.^[@bibr11-1758835918793849]^ *In vitro*, inhibition of pRb phosphorylation starts 4 h after exposure, is maximal at 16 h, and can be reversed after palbociclib is removed.^[@bibr11-1758835918793849]^ Hypophosphorylation of pRb hinders activation of the transcription factors necessary for S-phase entry, thus arresting cell cycle progression at the G1 phase and preventing DNA synthesis required for cellular replication and the unrestricted proliferation of malignant cells^[@bibr15-1758835918793849]^ ([Figure S1](http://journals.sagepub.com/doi/suppl/10.1177/1758835918793849)).

Differential cellular effects {#section8-1758835918793849}
-----------------------------

Human breast cancer cells that are ER+ or HER2 amplified with luminal features have thus far proven to be most sensitive to the CDK 4/6 inhibitory effects of palbociclib.^[@bibr10-1758835918793849],[@bibr16-1758835918793849]^ At clinically relevant concentrations, palbociclib has been shown to induce cellular senescence or the irreversible arrest of cell proliferation^[@bibr17-1758835918793849]^ in MCF-7 breast cancer cell lines that are ER+.^[@bibr18-1758835918793849]^ In a mechanistic study of palbociclib in combination with the antiestrogen treatment fulvestrant, which can also induce senescence, the senescence effect became additive, and cellular proliferation remained arrested with only a partial recovery occurring 5 days after the combined treatment was withdrawn.^[@bibr17-1758835918793849],[@bibr18-1758835918793849]^ In contrast, the effect of the same treatment was quite different in human bone marrow mononuclear cells that became pharmacologically quiescent (i.e. transiently arrested) rather than senescent when treated with palbociclib alone or palbociclib plus fulvestrant.^[@bibr18-1758835918793849]^ Because of this differential effect of treatment on bone marrow cells compared with breast tumor cells, the potential exists to reverse hematologic toxicities associated with exposure to palbociclib.^[@bibr18-1758835918793849]^ Furthermore, this treatment effect differentiates the cytostatic effect of palbociclib combined with endocrine therapy from the usual cytotoxic effects of chemotherapeutic agents on bone marrow progenitor cells leading to apoptosis.^[@bibr13-1758835918793849],[@bibr18-1758835918793849],[@bibr19-1758835918793849]^

Pharmacokinetics {#section9-1758835918793849}
----------------

Palbociclib is rapidly absorbed and detectable in the plasma of patients with Rb-positive solid tumors or non-Hodgkin lymphoma within 1 h of its oral administration^[@bibr20-1758835918793849],[@bibr21-1758835918793849]^ and is metabolized in the liver.^[@bibr8-1758835918793849]^ In patients with solid tumors, including ABC, and in healthy patients, the time to peak concentration ranges from 6 to 12 h.^[@bibr8-1758835918793849]^ Mean absolute bioavailability of palbociclib after a 125 mg dose was 46%, and the pharmacokinetics are linear, with exposure that increases proportionally with dose.^[@bibr8-1758835918793849]^ Following repeated once-daily dosing of palbociclib, a steady state was achieved within 8 days, and the median accumulation ratio reached 2.4 (range 1.5--4.2).^[@bibr8-1758835918793849]^ In patients with ABC, the mean elimination half life was 29 ± 5 h, and the geometric mean apparent oral clearance was 63.1 liters/h (29% coefficient variation).^[@bibr8-1758835918793849]^

An exposure--response analysis was recently conducted using data from PALOMA-2 to assess the effect of changes in palbociclib exposure (due to dose modification) on progression-free survival (PFS) in patients with HR+/HER2− ABC.^[@bibr22-1758835918793849]^ Patients in the palbociclib (125 mg once daily/3 weeks on/1 week off schedule) plus letrozole (2.5 mg once daily continuously) cohort were divided into four quantiles (Q1, Q2, Q3, and Q4) based on their palbociclib exposure.^[@bibr22-1758835918793849]^ The median PFS was similar in each quantile (24.9, 27.7, 25.7, and 24.0 months for Q1, Q2, Q3, and Q4, respectively) and substantially higher than the letrozole-only cohort (14.5 months), indicating that PFS duration was not associated with palbociclib exposure.^[@bibr22-1758835918793849]^ The results suggest that patients who had different exposure to palbociclib benefited similarly and that the dose reduction algorithm implemented in PALOMA-2 effectively managed palbociclib toxicity without significantly affecting efficacy.

Drug interactions {#section10-1758835918793849}
-----------------

The oxidative metabolism of palbociclib is primarily mediated by cytochrome P-450 (CYP) 3A.^[@bibr8-1758835918793849]^ Thus, a number of medications^[@bibr8-1758835918793849]^ and foods, including grapefruit products,^[@bibr23-1758835918793849]^ which are CYP3A inhibitors, may interact with palbociclib.^[@bibr8-1758835918793849],[@bibr24-1758835918793849]^ When multiple 200 mg doses of itraconazole, a strong CYP3A inhibitor, were coadministered with palbociclib, palbociclib exposure was markedly increased.^[@bibr25-1758835918793849]^ Although palbociclib was well tolerated, its peak concentration increased by 34%, and the area under the plasma concentration--time curve from time zero to infinity increased by 87% relative to a single 125 mg dose of palbociclib alone, which necessitates a palbociclib dose reduction to 75 mg if coadministration with strong CYP3A inhibitors is unavoidable.^[@bibr8-1758835918793849],[@bibr25-1758835918793849]^ In contrast, moderate to strong CYP3A inducers can decrease the concentration of circulating palbociclib.^[@bibr24-1758835918793849]^ Concurrent administration of palbociclib with other drugs that are also CYP3A4 substrates (i.e. metabolized by CYP3A) may necessitate dose reductions of these substrates, especially those with a narrow therapeutic index, to avoid increased plasma concentrations of these agents.^[@bibr24-1758835918793849]^ The coadministration of acid-reducing agents, such as the proton pump inhibitor rabeprazole, can substantially decrease palbociclib exposure in a fasted state, but this effect is mitigated by food.^[@bibr8-1758835918793849],[@bibr26-1758835918793849]^ Therefore, coadministration with acid-reducing agents is not thought to have any significant effect on palbociclib absorption when taken with food, as recommended. Although exposure to a single oral dose of palbociclib modestly increases in the fed state, its administration with food is recommended to avoid the variability in absorption that was observed in a small subset of patients dosed in a fasted state.^[@bibr8-1758835918793849],[@bibr27-1758835918793849]^

Based on clinical trial data, no clinically relevant drug--drug interactions have been reported when palbociclib has been coadministered with letrozole,^[@bibr16-1758835918793849],[@bibr28-1758835918793849]^ fulvestrant, or the luteinizing hormone releasing-hormone agonist goserelin.^[@bibr8-1758835918793849],[@bibr29-1758835918793849]^

Clinical efficacy of palbociclib {#section11-1758835918793849}
================================

Dosing {#section12-1758835918793849}
------

Palbociclib is taken orally with food, once daily (preferably at approximately the same time of day) for 3 weeks, followed by 1 week off treatment (i.e. a 3/1 schedule). Palbociclib is given in combination with either an AI or fulvestrant.^[@bibr8-1758835918793849]^ The recommended starting dose of palbociclib is 125 mg, and the available capsule strengths are 125 mg, 100 mg, and 75 mg to allow for dose reductions as necessary.^[@bibr8-1758835918793849]^ Palbociclib should be swallowed as a whole capsule and never be chewed, crushed, or ingested if capsules are broken, cracked, or otherwise not intact.^[@bibr8-1758835918793849]^

Efficacy {#section13-1758835918793849}
--------

The efficacy of palbociclib in combination with endocrine therapy as a treatment for ABC has been established in several clinical trials.^[@bibr19-1758835918793849],[@bibr30-1758835918793849][@bibr31-1758835918793849][@bibr32-1758835918793849]--[@bibr33-1758835918793849]^ Three randomized studies (phase II, PALOMA-1;^[@bibr19-1758835918793849]^ phase III, PALOMA-2 and -3^[@bibr30-1758835918793849][@bibr31-1758835918793849]--[@bibr32-1758835918793849]^) enrolled women with HR+/HER2− ABC. The PALOMA-1 and -2 trials included postmenopausal women who were naive to systemic treatment for advanced disease, whereas the PALOMA-3 trial included pre- or perimenopausal and postmenopausal women whose disease had progressed on prior endocrine therapy in the adjuvant or metastatic setting.^[@bibr19-1758835918793849],[@bibr30-1758835918793849][@bibr31-1758835918793849]--[@bibr32-1758835918793849]^ All three PALOMA studies met their primary endpoint of significantly prolonged investigator-assessed PFS compared with endocrine monotherapy according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.0 or 1.1). Key study design attributes and a trial efficacy summary are depicted in [Table 1](#table1-1758835918793849){ref-type="table"}.^[@bibr19-1758835918793849],[@bibr30-1758835918793849],[@bibr31-1758835918793849]^ At the time of the final analysis, patients in the palbociclib plus letrozole arms of the PALOMA-1 and -2 studies had achieved a significantly greater median PFS compared with that of patients receiving letrozole alone \[PALOMA-1, 20.2 *versus* 10.2 months, respectively; hazard ratio (HR) 0.49; 95% confidence interval (CI) 0.32−0.75; PALOMA-2, 24.8 *versus* 14.5 months; HR 0.58; 95% CI 0.46−0.72\].^[@bibr19-1758835918793849],[@bibr31-1758835918793849]^ In the PALOMA-3 study, median PFS in the palbociclib plus fulvestrant group was significantly longer than that in the placebo plus fulvestrant group (9.5 *versus* 4.6 months, respectively; HR 0.46; 95% CI 0.36−0.59) ([Table 1](#table1-1758835918793849){ref-type="table"}). After an updated analysis with longer follow up (through 23 October 2015) in the PALOMA-3 study, median PFS was 11.2 *versus* 4.6 months in the palbociclib plus fulvestrant *versus* placebo plus fulvestrant groups, respectively (HR 0.50; 95% CI 0.40−0.62; one-sided *p* \< 0.0001).^[@bibr34-1758835918793849]^ Similarly, in an updated analysis of the PALOMA-2 study, palbociclib plus letrozole was shown to consistently improve median PFS compared with placebo plus letrozole in the overall population (27.6 *versus* 14.5 months, respectively), as well as across patient subgroups, after approximately 37 months of follow up (data cutoff: 31 May 2017).^[@bibr35-1758835918793849]^

###### 

Key aspects and findings of the PALOMA studies.

![](10.1177_1758835918793849-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies, *N*                                                               PALOMA-1^[@bibr19-1758835918793849]^\              PALOMA-2^[@bibr31-1758835918793849]^\                                      PALOMA-3^[@bibr30-1758835918793849]^\
                                                                             (*N* = 165)                                        (*N* = 666)                                                                (*N* = 521)
  -------------------------------------------------------------------------- -------------------------------------------------- -------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  **Key study design aspects**                                               Phase II\                                          Phase III\                                                                 Phase III\
                                                                             Open label\                                        Placebo controlled\                                                        Placebo controlled\
                                                                             Randomized 1:1                                     Double blind\                                                              Double blind\
                                                                                                                                Randomized 2:1                                                             Randomized 2:1

  **Hormonal status**                                                        ER+/HER2−                                          ER+/HER2−                                                                  HR+/HER2−

  **Menopausal status**                                                      Postmenopausal                                     Postmenopausal                                                             Pre-/peri- and postmenopausal

  **Prior treatment**                                                        Systemic treatment naive for mBC/ABC               Systemic treatment naive for mBC/ABC                                       Progressed on prior endocrine therapy (adjuvant or metastatic)

  **Endocrine therapy**                                                      Letrozole                                          Letrozole                                                                  Fulvestrant

  **Treatment arms**                                                         Palbociclib + letrozole *versus* letrozole alone   Palbociclib + letrozole *versus* placebo + letrozole                       Palbociclib + fulvestrant *versus* placebo + fulvestrant^[‡](#table-fn3-1758835918793849){ref-type="table-fn"}^

  **Primary endpoint**                                                       Investigator-assessed PFS                          Investigator-assessed PFS                                                  Investigator-assessed PFS

  **Final analysis cutoff dates**                                            29 November 2013                                   26 February 2016^[\$](#table-fn2-1758835918793849){ref-type="table-fn"}^   16 March 2015

  **Efficacy parameters**                                                                                                                                                                                  

  **Median PFS, months**                                                     20.2 *versus* 10.2                                 24.8 *versus* 14.5                                                         9.5 *versus* 4.6

   **HR (95% CI)**                                                           0.49 (0.32−0.75)                                   0.58 (0.46−0.72)                                                           0.46 (0.36−0.59)

  *** p* value**                                                             One sided, 0.0004                                  Two sided, \<0.001                                                         Two sided, \<0.0001

  **PFS benefit, months**                                                    10.0                                               10.3                                                                       4.9

  **ORR % (95% CI)[\*](#table-fn1-1758835918793849){ref-type="table-fn"}**   55 (43−68) *versus* 39 (28−52)                     55 (50−61) *versus* 44 (37−52)                                             25 (20−30) *versus* 11 (6−17)

   **Odds ratio (95% CI)**                                                   N/A                                                1.55 (1.05−2.28)                                                           2.69 (1.43−5.26)

  *** p* value**                                                             0.047                                              0.03                                                                       \<0.0012

  **CBR % (95% CI)**                                                         81 (71−89) *versus* 58 (47−69)                     85 (81−88) *versus* 70 (64−76)                                             67 (61−72) *versus* 40 (32−47)

   **Odds ratio (95% CI)**                                                   N/A                                                2.39 (1.58−3.59)                                                           3.05 (2.07−4.61)

  *** p* value**                                                             \<0.001                                            \<0.001                                                                    \<0.0001

  **Median OS, months**                                                      37.5 *versus* 33.3                                                                                                            

   **HR (95% CI)**                                                           0.81 (0.49−1.35)                                   N/A                                                                        N/A

  *** p* value**                                                             0.42                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients with measurable disease.

Updated analysis available with a data cutoff date of 31 May 2017.^[@bibr35-1758835918793849]^

±Goserelin, dependent on menopausal status in both treatment arms.

Clinical benefit response = complete response plus partial response plus stable disease ⩾24 weeks.

Measurable disease was defined according to RECIST version 1.0 (PALOMA-1) and version 1.1 (PALOMA-2 and -3).

ABC, advanced breast cancer; CBR, clinical benefit rate; CI, confidence interval; ER+, estrogen receptor positive; HER2−, human epidermal growth factor receptor 2 negative; HR, hazard ratio; mBC, metastatic breast cancer; N/A, not available; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.

The efficacy of palbociclib plus endocrine therapy is consistent across various subgroups of patients in the PALOMA-1, -2, and -3 studies.^[@bibr30-1758835918793849],[@bibr35-1758835918793849][@bibr36-1758835918793849][@bibr37-1758835918793849][@bibr38-1758835918793849][@bibr39-1758835918793849][@bibr40-1758835918793849]--[@bibr41-1758835918793849]^ Compared with letrozole alone, palbociclib plus letrozole improved the median PFS and clinical benefit response rate, regardless of age group, histological subtype (ductal carcinoma or lobular), prior neoadjuvant/adjuvant systemic treatment, and site of metastatic disease (bone only, visceral, or distant metastases at other sites); the degree of benefit observed in the subgroups evaluated was consistent with that demonstrated in the overall study population.^[@bibr36-1758835918793849]^ In PALOMA-3, compared with fulvestrant alone, palbociclib plus fulvestrant improved median PFS regardless of menopausal status, the number of disease sites, the site of metastatic disease, and previous chemotherapy.^[@bibr30-1758835918793849]^ Additionally, based on an analysis of patients from PALOMA-2 and PALOMA-3, palbociclib plus endocrine therapy improved the median PFS compared with endocrine therapy alone in patients with and without visceral metastases.^[@bibr42-1758835918793849]^ The PALOMA-3 trial assessed the effect of two gene mutations on outcomes. Irrespective of *ESR1* mutation status^[@bibr37-1758835918793849]^ or *PIK3CA* mutation status,^[@bibr30-1758835918793849]^ palbociclib plus fulvestrant demonstrated a longer median PFS compared with fulvestrant alone. More recently explored results for efficacy in subgroups in the PALOMA-2 and -3 studies were presented at the 2017 American Society of Clinical Oncology Annual Meeting and the 2017 Annual San Antonio Breast Cancer Symposium and are summarized in [Table 2](#table2-1758835918793849){ref-type="table"}.^[@bibr35-1758835918793849],[@bibr39-1758835918793849][@bibr40-1758835918793849]--[@bibr41-1758835918793849]^ Subpopulation treatment effect pattern plot (STEPP) analysis presented at the 2018 American Society of Clinical Oncology Annual Meeting showed that the treatment effect of the addition of palbociclib to endocrine therapy was not impacted by the length of the initial treatment-free interval (TFI; PALOMA-2) or disease-free interval (DFI; PALOMA-3).^[@bibr43-1758835918793849]^ The median TFI in PALOMA-2 was 37.1 months for palbociclib plus letrozole and 30.9 months for letrozole plus placebo, with approximately 56% of patients having a TFI of over 2 years.^[@bibr43-1758835918793849]^ The median DFI in PALOMA-3 was 49.2 months for palbociclib plus fulvestrant *versus* 52.0 months for fulvestrant plus placebo, with over 80% of patients having had a DFI more than 2 years.^[@bibr43-1758835918793849]^ In addition, patient subgroup analyses of PALOMA-2 showed patients with either a low disease burden or a demonstrated sensitivity to endocrine monotherapy derived substantial PFS benefit from the combination of palbociclib plus letrozole (i.e. \>3 years median PFS).^[@bibr35-1758835918793849]^ Collectively, these findings demonstrate the clinical benefit of adding palbociclib to endocrine therapy for various subgroups of patients with ABC.

###### 

Subgroup analyses.

![](10.1177_1758835918793849-table2)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroups of interest in\                                                                                                         Palbociclib + fulvestrant arm                              
  PALOMA-3                                                                                                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Palbociclib exposure level** (data cutoff: 16 March 2015)^[@bibr39-1758835918793849]^                                                                                                      

   Median, C~avg~[\*](#table-fn7-1758835918793849){ref-type="table-fn"} Low, C~avg~ ⩽ median C~avg~ High, C~avg~ \> median C~avg~   78.2962.6595.87                                            Similar median PFS for low and high palbociclib exposure levels; see Kaplan--Meier plot for graphical depiction ([Figure S2](http://journals.sagepub.com/doi/suppl/10.1177/1758835918793849))

                                                                                                                                    Palbociclib + fulvestrant *versus* placebo + fulvestrant   

                                                                                                                                    Patients,\                                                 Median PFS (95% CI), months;\
                                                                                                                                    *n*                                                        HR \[95% CI\]

  **Predictors of prolonged benefit** (data cutoff: 31 August 2016)^[@bibr40-1758835918793849]^                                                                                                

   No liver metastasis                                                                                                              220 *versus* 93                                            13.9 (12.0--16.6) *versus* 7.4 (5.4--10.9);\
                                                                                                                                                                                               0.52 \[0.38--0.70\]

   Patients with one prior therapy                                                                                                  78 *versus* 45                                             13.3 (10.9--16.6) *versus* 5.4 (3.4--8.5);\
                                                                                                                                                                                               0.42 \[0.26--0.67\]

   Patients with one or two disease sites                                                                                           206 *versus* 111                                           13.4 (11.3--15.9) *versus* 5.6 (3.9--8.5);\
                                                                                                                                                                                               0.50 \[0.37--0.66\]

  Subgroups of interest in\                                                                                                         Palbociclib + letrozole *versus* placebo + letrozole       
  PALOMA-2                                                                                                                                                                                     

  Patients,\                                                                                                                        Median PFS (95% CI), months;\                              
  *n*                                                                                                                               HR \[95% CI\]                                              

  **Disease sites**                                                                                                                                                                            

  Data cutoff: 26 February 2016^[@bibr41-1758835918793849]^                                                                                                                                    

    Visceral disease^[@bibr42-1758835918793849]^                                                                                    214 *versus* 110                                           19.3 (16.4--22.2) *versus* 12.9 (8.4--16.6);\
                                                                                                                                                                                               0.63 \[0.47--0.85\]

    Nonvisceral disease^[@bibr42-1758835918793849]^                                                                                 230 *versus* 112                                           NR (25.1--NE) *versus* 16.8 (13.7--22.2);\
                                                                                                                                                                                               0.50 \[0.36--0.70\]

    Bone-only disease                                                                                                               103 *versus* 48                                            NR (24.8--NE) *versus* 11.2 (8.2--22.0);\
                                                                                                                                                                                               0.36 \[0.22--0.59\]

    Nonvisceral disease excluding bone only                                                                                         128 *versus* 64                                            27.6 (22.4--NE) *versus* 21.9 (13.8--NE);\
                                                                                                                                                                                               0.65 \[0.42--1.03\]

    Liver involvement                                                                                                               75 *versus* 46                                             13.7 (10.9--16.6) *versus* 8.4 (5.5--12.9);\
                                                                                                                                                                                               0.62 \[0.41--0.95\]

    Lung involvement, including pleura                                                                                              171 *versus* 84                                            22.2 (16.8--25.4) *versus* 13.6 (8.4--18.5);\
                                                                                                                                                                                               0.59 \[0.41--0.83\]

  Data cutoff: 31 May 2017^[@bibr35-1758835918793849]^                                                                                                                                         

    Visceral disease                                                                                                                214 *versus* 110                                           19.3 (16.4--24.2) *versus* 12.3 (8.4--16.4);\
                                                                                                                                                                                               0.62 \[0.47--0.81\]

    Nonvisceral disease                                                                                                             230 *versus* 112                                           35.9 (27.7--NE) *versus* 17.0 (13.8--24.8);\
                                                                                                                                                                                               0.50 \[0.37--0.67\]

    Bone-only disease                                                                                                               103 *versus* 48                                            36.2 (27.6--NE) *versus* 11.2 (8.2--22.0);\
                                                                                                                                                                                               0.41 \[0.26--0.63\]

    No bone-only disease^[\$](#table-fn8-1758835918793849){ref-type="table-fn"}^                                                    341 *versus* 174                                           24.2 (19.4--27.7) *versus* 14.5 (12.9--18.5);\
                                                                                                                                                                                               0.62 \[0.50--0.78\]

    DFI^[‡](#table-fn9-1758835918793849){ref-type="table-fn"}^ \>12  months                                                         179 *versus* 93                                            30.3 (24.8--NE) *versus* 13.8 (8.8--18.2);\
                                                                                                                                                                                               0.55 \[0.40--0.76\]

    DFI^[‡](#table-fn9-1758835918793849){ref-type="table-fn"}^⩽12 months                                                            98 *versus* 48                                             16.6 (13.9--24.2) *versus* 11.0 (5.6--12.9);\
                                                                                                                                                                                               0.48 \[0.32--0.72\]

    DFI^[‡](#table-fn9-1758835918793849){ref-type="table-fn"}^ \>2 years                                                            154 *versus* 77                                            38.5 (27.5--NE) *versus* 16.6 (13.7--23.5);\
                                                                                                                                                                                               0.52 \[0.36--0.75\]

    DFI^[‡](#table-fn9-1758835918793849){ref-type="table-fn"}^ \>5 years                                                            90 *versus* 46                                             38.6 (27.6--NE) *versus* 23.5 (16.3--32.2);\
                                                                                                                                                                                               0.60 \[0.36--1.00\]

    DFI^[‡](#table-fn9-1758835918793849){ref-type="table-fn"}^ \>10 years                                                           32 *versus* 23                                             NR (30.4--NE) *versus* 23.5 (16.6--NE);\
                                                                                                                                                                                               0.44 \[0.19--1.03\]

    Prior ET                                                                                                                        250 *versus* 126                                           24.2 (18.8--27.6) *versus* 11.2 (8.4-14.5);\
                                                                                                                                                                                               0.54 \[0.42--0.71\]

    No prior ET                                                                                                                     194 *versus* 96                                            30.3 (24.5--35.7) *versus* 21.9 (15.9--27.4);\
                                                                                                                                                                                               0.59 \[0.43--0.80\]

    Age \<65 years                                                                                                                  263 *versus* 141                                           23.2 (19.3--27.6) *versus* 13.7 (11.0--16.6);\
                                                                                                                                                                                               0.55 \[0.43--0.70\]

    Age ⩾65 years                                                                                                                   181 *versus* 81                                            30.6 (27.6--NE) *versus* 19.1 (11.0--30.4);\
                                                                                                                                                                                               0.60 \[0.43--0.86\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Average concentration of palbociclib over the entire treatment (C~avg~) was derived from ADI divided by estimated apparent oral clearance (CL/F) for each patient; C~avg~ (ng/ml) = \[ADI / (CL/F)\]/24 h.

Per tumor site.

Protocol-defined DFI refers to DFI since completion of prior (neo)adjuvant therapy and onset of metastatic disease or disease recurrence.

ADI, average daily dose intensity; ASCO, American Society of Clinical Oncology; C~avg~, time-independent average daily palbociclib concentration; CI, confidence interval; DFI, disease-free interval; ET, endocrine therapy; HR, hazard ratio; NE, not estimable; NR, not reached; PFS, progression-free survival; SABCS, San Antonio Breast Cancer Symposium.

Of the PALOMA studies, only the PALOMA-1 data have thus far matured for assessment of overall survival (OS). There was no statistically significant survival benefit as a result of adding palbociclib to letrozole *versus* letrozole monotherapy in PALOMA-1; although, previous analyses have indicated that a longer median survival post progression can dilute an OS comparison and necessitate a larger sample size to sufficiently power the detection of a significant difference in the advanced disease setting ([Table 1](#table1-1758835918793849){ref-type="table"}).^[@bibr44-1758835918793849],[@bibr45-1758835918793849]^

Safety of palbociclib {#section14-1758835918793849}
=====================

In a comprehensive long-term safety analysis, safety data from the three PALOMA studies were combined (*N* = 872 safety population) to characterize the safety profile of palbociclib plus endocrine therapy.^[@bibr46-1758835918793849]^ Safety evaluations extended beyond the final analysis cutoff dates for the primary endpoints of PFS for PALOMA-1 (2 January 2015) and -3 (31 July 2015) and covered a 3-year period.^[@bibr46-1758835918793849]^ Among all three PALOMA studies, neutropenia \[cluster of preferred terms (PTs), all causalities\] was the most commonly reported toxicity (all grade, 75.7% patients) and peaked during the first 6 months of treatment ([Figure 1](#fig1-1758835918793849){ref-type="fig"}); moreover, mean grade 3--4 neutropenia remained stable over time, indicative of a lack of cumulative toxicity following prolonged palbociclib treatment.^[@bibr46-1758835918793849]^ Unlike the DNA damage and apoptosis caused by myeloablative and cytotoxic chemotherapeutic agents, which is associated with slower recovery, palbociclib-induced neutropenia arises from the temporary growth arrest (quiescence) of dividing myeloid progenitor cells/neutrophil precursors. Palbociclib growth arrest is rapidly reversible upon removal of the drug.^[@bibr18-1758835918793849]^ Myelosuppression of this nature can be effectively managed by close monitoring of complete blood counts, particularly early during treatment,^[@bibr47-1758835918793849]^ and *via* an established dose modification schema that includes dose interruptions, dose reductions, or a delay in starting treatment cycles ([Figure 2](#fig2-1758835918793849){ref-type="fig"}),^[@bibr8-1758835918793849]^ without any negative impact on efficacy.^[@bibr47-1758835918793849]^ Other safety data have shown no correlation between grade 3--4 neutropenia and serious infections or infections in either the PALOMA-1 or -3 studies, respectively.^[@bibr36-1758835918793849],[@bibr47-1758835918793849]^ Similarly, findings from a single center retrospective study of 344 patients with ER+ metastatic breast cancer who received palbociclib as standard of care showed that dose reductions and delays did not negatively affect PFS.^[@bibr48-1758835918793849]^

![Incidence of (a) hematologic and (b) nonhematologic adverse events pooled from the three PALOMA studies by 6-month treatment intervals. Includes treatment-emergent adverse events of any grade and all causalities occurring in at least 15% of patients treated with palbociclib plus endocrine therapy.\
^a^Clusters of preferred terms (PTs) were used as follows: anemia includes the PTs anemia, hematocrit decreased, and hemoglobin decreased; infections include any reported PT of the system organ class infections and infestations; leukopenia includes the PTs leukopenia and white blood cell count decreased; neutropenia includes the PTs neutropenia or neutrophil count decreased; stomatitis includes the PTs aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort, oropharyngeal pain, and stomatitis; thrombocytopenia includes the PTs platelet count decreased and thrombocytopenia.\
^b^Patient percentages were calculated using the number of patients at each time interval as the denominator.](10.1177_1758835918793849-fig1){#fig1-1758835918793849}

![Recommended palbociclib dose modifications for (a) neutropenia and (b) thrombocytopenia.^[@bibr8-1758835918793849]^ For patients who experience a maximum of grade 1 or 2 neutropenia in the first six cycles, monitor complete blood counts every 3 months in subsequent cycles at the beginning of the cycle and as clinically indicated. Grading according to CTCAE 4.0.\
ANC, absolute neutrophil count; CBC, complete blood count; CTCAE, Common Terminology Criteria for Adverse Events.](10.1177_1758835918793849-fig2){#fig2-1758835918793849}

The most common all-grade nonhematologic adverse events associated with palbociclib in the PALOMA pooled safety analysis were infections (36.7% for the cluster of PTs), fatigue (32.2%), nausea (28.1%), and stomatitis (23.2% for the cluster of PTs). The incidence of nonhematologic adverse events associated with palbociclib generally were greatest during the first 6 months of treatment and largely decreased over time ([Figure 1](#fig1-1758835918793849){ref-type="fig"}).

A thorough study of the effects on QT interval prolongation of any new drugs with systemic bioavailability is recommended by the FDA^[@bibr49-1758835918793849]^ and is particularly important in patients with cancer who often have several risk factors for cardiac disease and QT prolongation.^[@bibr50-1758835918793849]^ In a QT substudy of 125 patients in the PALOMA-2 trial, none of the patients in the palbociclib plus letrozole group had a 480 ms or higher maximum postbaseline study-specific correction factor (QTcS) or Frederica's correction (QTcF) or a 60 ms or higher maximum increase from time-matched baseline QTcS or QTcF.^[@bibr51-1758835918793849],[@bibr52-1758835918793849]^ Moreover, the upper bounds of the one-sided 95% CIs for QTcS, QTcF, and Bazett's correction at all time points and at maximum steady-state concentration following repeated dosing with palbociclib 125 mg were less than 10 ms.^[@bibr51-1758835918793849],[@bibr52-1758835918793849]^ Thus, palbociclib administered in combination with letrozole at the recommended therapeutic doses had no clinically relevant effect on the QT interval in patients with ABC enrolled in the substudy.

Overall, the long-term safety profile of palbociclib demonstrated by the PALOMA pooled safety analysis was consistent with previously reported safety findings for palbociclib plus endocrine therapy.^[@bibr46-1758835918793849]^

Patient-reported outcomes {#section15-1758835918793849}
=========================

The goal of treatment for patients with ABC is palliative and primarily aimed at maintaining quality of life (QoL) while delaying disease progression and prolonging survival.^[@bibr6-1758835918793849]^ However, improvements in efficacy as a result of adding additional treatments to a standard noncurative therapeutic regimen should not be accompanied by an increased toxicity burden that causes significant deterioration in the functioning or symptoms for patients.^[@bibr6-1758835918793849]^ The impact of palbociclib plus letrozole (as first-line therapy for ABC) or palbociclib plus fulvestrant as second-line therapy for patients with disease progression on prior endocrine therapy for advanced disease versus the same respective endocrine monotherapy on patient-reported QoL parameters was assessed in HR+/HER2− patients with ABC in the PALOMA-2 and -3 studies.^[@bibr6-1758835918793849],[@bibr53-1758835918793849]^

In PALOMA-2, patient-reported outcomes (PROs) were assessed in patients previously untreated with systemic therapy for ABC randomized to receive letrozole with or without palbociclib (on day 1 of cycles 2 and 3 and every subsequent alternate cycle from cycle 5 until end of treatment) using the Functional Assessment of Cancer Therapy−Breast (FACT-B) questionnaires, including FACT-General (FACT-G) and the Breast Cancer Subscale.^[@bibr53-1758835918793849]^ There was no significant difference between palbociclib plus letrozole and letrozole monotherapy in overall change from baseline in FACT-B or FACT-G total scores, despite the longer duration of treatment in the combination arm, and no significant difference in FACT-B health-related QoL (HRQoL) based on FACT-B total scores. These findings suggest palbociclib plus letrozole maintained HRQoL in patients with advanced disease in first-line therapy while prolonging PFS. PROs were also assessed using the Euro-QOL 5 Dimension (EQ-5D) questionnaire, a two-part, self-administered, standardized measure of health status that includes the EQ-5D Index (comprising five dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression) and a visual analog scale (VAS).^[@bibr54-1758835918793849]^ Results showed that general health status and EQ-5D index scores were maintained from baseline in patients treated with palbociclib plus letrozole with no statistically significant differences between treatment arms.^[@bibr54-1758835918793849]^

In patients who developed resistance to prior endocrine therapy for advanced disease (PALOMA-3), PROs during treatment were assessed on day 1 of cycles 1--4 and alternate subsequent cycles (starting with cycle 6) using the European Organisation for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30 version 3.0) and its breast cancer module, QLQ-BR23. In the palbociclib plus fulvestrant arm *versus* the fulvestrant arm, estimated overall global QoL scores were significantly improved (66.1 *versus* 63.0, respectively; *p* = 0.03), patient-reported pain significantly improved from baseline (--3.3 *versus* 2.0; *p* = 0.001), and time to deterioration in global QoL and pain were significantly delayed (HR 0.64; 95% CI 0.45--0.91; *p *\< 0.007; and HR 0.64; 95% CI 0.49--0.85; *p *\< 0.001, respectively).^[@bibr6-1758835918793849]^ EORTC QLQ-BR23 functioning domains and the symptom domains for breast, arms, and systemic therapy side effects were similar between treatments.^[@bibr6-1758835918793849]^

Palbociclib in special populations {#section16-1758835918793849}
==================================

Elderly patients {#section17-1758835918793849}
----------------

No differences in the safety or efficacy of palbociclib have been shown between younger and older patients.^[@bibr8-1758835918793849],[@bibr36-1758835918793849]^ Therefore, no dose adjustments are required based solely on age in patients taking palbociclib.^[@bibr8-1758835918793849]^ A subgroup analysis of patients from PALOMA-1 demonstrated improvement in median PFS with palbociclib plus letrozole *versus* letrozole alone in patients aged less than 65 years (HR 0.32; 95% CI 0.18--0.54; *p *\< 0.00001) and in patients aged 65 years and over (HR 0.505; 95% CI 0.269--0.948; *p *= 0.0155).^[@bibr36-1758835918793849]^ A pooled analysis of data from elderly patients in the PALOMA-1, -2, and -3 studies showed that palbociclib combined with endocrine therapy *versus* endocrine therapy alone improved PFS in patients aged 65--74 years (HR 0.66; 95% CI 0.45--0.97; *p *= 0.0162) and those aged 75 years and over (HR 0.31; 95% CI 0.16--0.61; *p *= 0.0002).^[@bibr55-1758835918793849]^ Moreover, findings from the pooled analysis demonstrated no new safety concerns in elderly patients taking palbociclib.^[@bibr55-1758835918793849]^

Patients with hepatic or renal impairment {#section18-1758835918793849}
-----------------------------------------

Palbociclib exposure is not altered in patients with mild hepatic impairment \[total bilirubin ⩽ upper limit of normal (ULN) and aspartate aminotransferase (AST) \> ULN, or total bilirubin \>1.0--1.5 × ULN and any AST\] or in patients with mild \[60 ml/min ⩽ creatinine clearance (CrCl) \<90 ml/min\] or moderate renal impairment (30 ml/min ⩽ CrCl \<60 ml/min) and therefore does not typically require dose adjustments.^[@bibr8-1758835918793849]^ Recently, palbociclib has also been studied in patients with moderate or severe hepatic impairment or severe renal impairment.

A phase I study evaluating the pharmacokinetics of palbociclib in subjects with moderate to severely impaired hepatic function demonstrated that plasma palbociclib unbound exposure was decreased by 17% in subjects with mild hepatic impairment, while increasing by 34% and 77% in subjects with moderate or severe hepatic impairment, respectively, compared with subjects with normal hepatic function. Similarly, peak palbociclib unbound exposure increased by approximately 7%, 38%, and 72% in subjects with mild, moderate, and severe hepatic impairment, respectively.^[@bibr56-1758835918793849]^ These findings demonstrate that no dose adjustment is required for patients with mild or moderate hepatic impairment whereas the recommended dose of palbociclib for patients with severe hepatic impairment should be 75 mg once daily on a 3/1 schedule (i.e. 3 weeks on, followed by 1 week off palbociclib treatment).^[@bibr56-1758835918793849]^

A phase I study evaluating the pharmacokinetics of palbociclib in subjects with severe renal impairment demonstrated that plasma palbociclib total exposure increased modestly (range 31--42%), and maximum plasma concentration also increased but to a lesser extent (range 12--17%) after administration of a single oral 125 mg dose of palbociclib in subjects with mild, moderate, or severe renal impairment compared with subjects who had normal renal function.^[@bibr57-1758835918793849]^ No obvious trend was observed for unbound drug in plasma in subjects with worsening renal function. Additionally, in patients with normal renal function, and those with mild to severe renal impairment, single oral 125 mg doses of palbociclib were well tolerated.^[@bibr57-1758835918793849]^

Real-world patients {#section19-1758835918793849}
-------------------

A retrospective cohort study was conducted to assess real-world treatment patterns and outcomes, both pre and post approval, of palbociclib in women with newly diagnosed HR+/HER2-- metastatic breast cancer.^[@bibr58-1758835918793849]^ Additionally, the impact of NCCN guidelines for premenopausal women on treatment patterns and outcomes following palbociclib approval *versus* prior to the availability of CDK 4/6 inhibitors was assessed. The study used electronic health records data from the Flatiron Health Analytic metastatic breast cancer database (metastatic diagnosis from January 2011 to March 2017).^[@bibr58-1758835918793849]^ Overall, 10% (*n* = 415) of women were premenopausal (defined as age ⩽50 years) and 90% (*n* = 3576) were postmenopausal (age \>50 years) at the index date.^[@bibr58-1758835918793849]^ Treatment patterns for initial endocrine therapy showed that after approval of palbociclib, approximately 30% of women aged up to 50 years were administered a palbociclib-containing regimen, with or without ovarian suppression, and this proportion was comparable to that observed in women aged over 50 years (27%).^[@bibr58-1758835918793849]^ Consistent with NCCN guidelines, the frequency of palbociclib use was similar for younger and older patients with palbociclib most commonly combined with letrozole in both age groups. In addition, the proportion of younger women who had initiated endocrine-based treatment with an AI alone prior to palbociclib approval was reduced by half post approval (46% *versus* 23%); however, the increased use of AI--palbociclib combinations (which increased to 25% after approval) offsets this reduction.^[@bibr58-1758835918793849]^ Results from this analysis show that in accordance with American Society of Clinical Oncology and NCCN guidelines, palbociclib has been incorporated into standard care in the US for women with HR+/HER2-- metastatic breast cancer, irrespective of age.^[@bibr58-1758835918793849]^

Another retrospective observational study also used data from the Flatiron Health Analytic metastatic breast cancer database to analyze real-world population characteristics and utilization patterns in patients who had initiated treatment with palbociclib on or after the date of palbociclib approval (3 February 2015) to 31 March 2017.^[@bibr59-1758835918793849]^ Of the 1871 patients in the analysis who initiated treatment with palbociclib, 98.4% were women (pre- and postmenopausal) and 1.6% were men. Overall, 39.1% of patients received palbociclib as first-line therapy, 31.9% as second-line, and 40.9% as third-line or later therapy.^[@bibr59-1758835918793849]^ Among women who had initiated palbociclib with an AI, 45.7% initiated it as first-line therapy, 23.8% as second-line therapy, and 30.6% as third-line or later therapy. Among women who had initiated palbociclib in combination with fulvestrant, 22.3% initiated it as first-line therapy, 32.5% as second-line therapy, and 45.2% as third-line or later therapy. Moreover, among all patients who received first-line palbociclib, 65.7% used palbociclib in combination with an AI. In accordance with the product label, the majority of patients initiated palbociclib at the recommended 125 mg dose.^[@bibr59-1758835918793849]^

Ongoing and future palbociclib studies {#section20-1758835918793849}
======================================

As of February 2018, there were 70 ongoing breast cancer interventional studies that involve palbociclib. Select ongoing clinical trials to further assess the role of palbociclib in breast cancer are shown in [Table 3](#table3-1758835918793849){ref-type="table"}. Currently, ongoing studies are evaluating the safety and efficacy of palbociclib in combination with endocrine therapy in patients with early breast cancer (adjuvant and neoadjuvant) and HER2+ metastatic breast cancer in combination with endocrine therapy, pertuzumab, and trastuzumab. Palbociclib is also being studied in patients with other tumor types, including gastrointestinal, and lung cancers.

###### 

Select palbociclib breast cancer clinical studies.

![](10.1177_1758835918793849-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (phase)\                                                                Breast cancer setting                                                                 Menopausal status                                                     Estimated/no. patients   Treatment arms                                                                                                                                                       Primary endpoint
  [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier\                                                                                                                                                                                                                                                                                                                                                                             
  Estimated completion[\*](#table-fn11-1758835918793849){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                             
  ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------
  PACE (phase II)\                                                              HR+/HER2−ABC and progression despite prior CDK 4/6 inhibition and endocrine therapy   Pre-/postmenopausal                                                   220                      Fulvestrant *versus*\                                                                                                                                                PFS
  NCT03147287                                                                                                                                                                                                                                                        fulvestrant + upfront palbociclib *versus*\                                                                                                                          
                                                                                                                                                                                                                                                                     fulvestrant + palbociclib + avelumab                                                                                                                                 

  PALOMA-1 (phase II)\                                                          ER+/HER2− ABC and naive to systemic anticancer therapy for ABC                        Postmenopausal                                                        165                      Palbociclib + letrozole *versus* letrozole                                                                                                                           Investigator-assessed PFS
  NCT00721409                                                                                                                                                                                                                                                                                                                                                                                                                             

  PALOMA-2 (phase III)\                                                         ER+/HER2− ABC and naive to systemic anticancer therapy for ABC                        Postmenopausal                                                        666                      Palbociclib + letrozole *versus* placebo + letrozole                                                                                                                 Investigator-assessed PFS
  NCT01740427                                                                                                                                                                                                                                                                                                                                                                                                                             

  PALOMA-3 (phase III)\                                                         HR+/HER2− ABC with prior endocrine resistance                                         Pre-/peri- and postmenopausal                                         521                      Palbociclib + fulvestrant *versus* placebo + fulvestrant                                                                                                             Investigator-assessed PFS
  NCT01942135                                                                                                                                                                                                                                                                                                                                                                                                                             

  PALOMA-4 (phase III)\                                                         ER+/HER2− ABC and naive to systemic anticancer therapy for ABC                        Postmenopausal                                                        330\                     Palbociclib + letrozole *versus* placebo + letrozole                                                                                                                 PFS
  NCT02297438 April 2018                                                                                                                                                                                                                    Asian                                                                                                                                                                                         

  PEARL (phase III)\                                                            HR+/HER2− mBC with prior endocrine resistance                                         Postmenopausal                                                        600                      Palbociclib + exemestane or fulvestrant *versus* capecitabine                                                                                                        Investigator-assessed PFS
  NCT02028507\                                                                                                                                                                                                                                                                                                                                                                                                                            
  September 2019                                                                                                                                                                                                                                                                                                                                                                                                                          

  PENELOPE-B (phase III)\                                                       HR+/HER2− normal,^[\$](#table-fn12-1758835918793849){ref-type="table-fn"}^\           Pre-/postmenopausal                                                   1100                     Palbociclib + standard of care *versus* placebo + standard of care                                                                                                   iDFS
  NCT01864746\                                                                  at high risk of relapse after neoadjuvant chemotherapy and surgery                                                                                                                                                                                                                                                                                        
  December 2020                                                                                                                                                                                                                                                                                                                                                                                                                           

  PALLAS (phase III)\                                                           HR+/HER2− EBC in adjuvant therapy setting                                             Pre-/postmenopausal women or men with stage II/IIA/III invasive EBC   4600                     Palbociclib + endocrine therapy *versus* endocrine therapy                                                                                                           iDFS
  NCT02513394\                                                                                                                                                                                                                                                                                                                                                                                                                            
  September 2020                                                                                                                                                                                                                                                                                                                                                                                                                          

  PALLET (phase II)\                                                            ER+/HER2− early invasive BC, in the neoadjuvant setting                               Postmenopausal                                                        306                      Letrozole *versus* letrozole then letrozole + palbociclib *versus* palbociclib then palbociclib + letrozole *versus* letrozole + palbociclib                         Change in Ki67 from baseline to 14 weeks and CCR
  NCT02296801\                                                                                                                                                                                                                                                                                                                                                                                                                            
  July 2017                                                                                                                                                                                                                                                                                                                                                                                                                               

  PATINA (phase III)\                                                           HR+/HER2+ mBC or not amendable for resection/radiation therapy with curative intent   Any/none (i.e. male)                                                  496                      Palbociclib + trastuzumab/pertuzumab + letrozole/anastrozole/exemestane/fulvestrant *versus* trastuzumab/pertuzumab + letrozole/anastrozole/exemestane/fulvestrant   Investigator-assessed PFS
  NCT02947685\                                                                                                                                                                                                                                                                                                                                                                                                                            
  October 2020                                                                                                                                                                                                                                                                                                                                                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Final data collection date for the primary outcome measure.

Normal indicates with an immunohistochemistry score 0−1 or a fluorescent *in situ* hybridization negative result (that is, an *in-situ* hybridization ratio \<2.0 status) preferably based on tissue from postneoadjuvant residual invasive disease or a core biopsy of the breast, or if no other tissue is available, the residual tumor of the lymph node.

ABC, advanced breast cancer; BC, breast cancer; CCR, complete clinical response; CDK 4/6, cyclin-dependent kinases 4 and 6; EBC, early breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; iDFS, invasive disease-free survival; mBC, metastatic breast cancer; PFS, progression-free survival.

Current literature on the real-world use of palbociclib in clinical practice is limited, but findings from ongoing real-world retrospective studies, such as those presented above analyzing data from the Flatiron Health Analytic database, will provide important information regarding the use of palbociclib in clinical practice. An ongoing retrospective, longitudinal, observational study showed that demographic and clinical characteristics of patients initiating treatment with palbociclib in the real world generally are similar to those in US studies.^[@bibr60-1758835918793849]^ Another retrospective, observational study is currently assessing the demographic and clinical characteristics and treatment patterns of patients initiating palbociclib in the real world.^[@bibr61-1758835918793849]^ At present, a prospective, noninterventional study of palbociclib in ABC treatment is underway to understand prescribing and treatment patterns in routine clinical practice; ABC treatment prior to, during, and after palbociclib; patient perceived tolerability; geriatric assessment in elderly patients; and biomarkers underlying resistance or response mechanisms to palbociclib treatment.

Conclusion {#section21-1758835918793849}
==========

Palbociclib is a first-in-class CDK 4/6 inhibitor indicated for combination with endocrine therapy as first-line treatment and after progression on prior endocrine therapy in patients with HR+/HER2-- metastatic breast cancer or ABC, and over 70,000 patients in the US and over 100,000 patients worldwide are estimated to have been treated with palbociclib to date. Clinical studies have demonstrated that palbociclib in combination with endocrine therapy is efficacious and tolerable, including in several subgroups of patients, and furthermore, it maintains HRQoL. Although a comprehensive review of the class of CDK 4/6 inhibitors is beyond the scope of this publication, it should be noted that other CDK 4/6 inhibitors have been approved more recently (FDA approval of ribociclib as of 13 March 2017 and abemaciclib as of 28 September 2017). In clinical trials of CDK 4/6 inhibitors, notable differences between the adverse event profiles of palbociclib and the other two agents have become apparent and should be taken into consideration when selecting an appropriate therapy.^[@bibr62-1758835918793849][@bibr63-1758835918793849]--[@bibr64-1758835918793849]^ Future clinical studies are ongoing to assess palbociclib use in the real world and as a potential treatment for patients with HR+ early breast cancer.

Supplemental Material {#section22-1758835918793849}
=====================
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